Jyong Biotech Ltd. (MENS) company profile
Close on Nov 18, 2026Market cap $141.41MP/E –Yield –
About Jyong Biotech
Pharmaceutical Preparations, SIC 2834
Jyong Biotech Ltd. is a clinical-stage biopharmaceutical company focused on the development of botanical drug products. The company's primary focus is on advancing its core drug candidate, Botreso, which is undergoing clinical development for the initial treatment of benign prostatic hyperplasia and lower urinary tract symptoms (BPH/LUTS). In addition to Botreso, the company explores other potential indications, such as prostate cancer prevention, as well as candidates designated as PCP and IC. Its future customer base encompasses prospective patients, healthcare providers, and third-party payors within the medical community.
All of the company's key drug candidates remain in preclinical or clinical development phases without commercial sales or marketing approval. The company conducts research and clinical development activities across multiple jurisdictions, including the United States and Taiwan, while considering broader international regulatory pathways. Jyong Biotech Ltd. maintains its principal executive offices and headquarters in New Taipei City, Taiwan, and is incorporated under the laws of the Cayman Islands.
Summary of the business section of Jyong Biotech's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Jyong Biotech Ltd.
- Headquarters
- New Taipei City, Taiwan
- Address
- 23f-3, No.95, Sec. 1, Xintai 5th Rd., Xizhi Dist.
- Phone
- (8862) 27325205
- Website
- jyongbio.com
- Employees
- 15, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- E9
- Auditor
- WWC, P.C, San Mateo, California
Stock & identifiers
- Ticker
- MENS
- Exchange
- Nasdaq
- IPO date
- Jun 18, 2025
- Shares outstanding
- 76M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Emerging growth company
- SEC CIK
- 1954488
- CUSIP
- G83116106
- FIGI
- BBG01HZQMX71
- Share class FIGI
- BBG01HZQMY60
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Fu-Feng Kuo | CEO, Director | 25,349,500 |
| Wei (Vivi) Zhang | CFO | – |
| Ming Tsan Hsu | Director | 3,000 |
| Hung-Shu Fan | Director | – |
| Feng-Lin Hsu | Director | 3,000 |
| Pang-Chieh Chi | Director | – |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jun 18, 2025
- Offer price
- $7.50
- Exchange
- Nasdaq
- First trading day
- Jun 17, 2025
- First-day close
- $10.11+34.8%
- Lock-up ends (est.)
- Dec 14, 2025
“The initial public offering price of our ordinary shares is US$7.50 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 29, 2026 | Late filing | Notification of late filing |
| Jun 18, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 12, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?